Kymera Therapeutics saw the highest growth of 2.24% in patent filings in May and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Kymera Therapeutics‘s patent filings and grants. Buy the databook here.
Kymera Therapeutics has been focused on protecting inventions in European Patent Office(EPO) with seven publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings with nearly 12% of filings. The World Intellectual Property Organization(WIPO), United States(US), European Patent Office(EPO), and Australia(AU) patent Office are among the top ten patent offices where Kymera Therapeutics is filings its patents. Among the top granted patent authorities, Kymera Therapeutics has 100% of its grants in United States(US).
Roche could be the strongest competitor for Kymera Therapeutics
Patents related to rare diseases and climate change lead Kymera Therapeutics's portfolio
Kymera Therapeutics has the highest number of patents in rare diseases followed by, climate change. For rare diseases, nearly 100% of patents were filed and 100% of patents were granted in Q2 2024.
Chronic kidney disease (chronic renal failure) related patents lead Kymera Therapeutics portfolio followed by petrochemicals, and neuroblastoma
Kymera Therapeutics has highest number of patents in chronic kidney disease (chronic renal failure) followed by petrochemicals, neuroblastoma, lymphoma, and hodgkin lymphoma (b-cell hodgkin lymphoma).
For comprehensive analysis of Kymera Therapeutics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.